Overview of studies that investigated the molecular remission rates among previously untreated patients with Ann Arbor stage II to IV MCL
| . | . | . | . | . | MRD negativity . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cohort . | Reference . | Induction . | Consolidation/maintenance . | MRD detection method . | At end of induction . | After consolidation . | ||||
| PB or BM . | PB . | BM . | PB or BM . | PB . | BM . | |||||
| Nordic MCL1 | 5 | 6 × maxiCHOP | ASCT | MFC or PCR | NR (0 of 16 stem cell products) | NR | NR | NR | NR | 38% of 13 |
| Kiel single-center report | 16 | 6 × CHOP-like | ASCT | RQ-PCR | 0 of 9 (6% of 17 stem cell products) | NR | NR | 52% of 27 | NR | NR |
| MCL Younger and MCL elderly | 4, 24, 25 | 6-8 × R-CHOP | ASCT or rituximab maintenance or interferon alpha maintenance | RQ-PCR | 40% of 225 | 53% of 216 | 34% of 156 | 48% of 209 | 58% of 205 | 56% of 117 |
| MCL Younger | 4, 25 | 6 × R-CHOP | ASCT | RQ-PCR | 34% of 126 | 47% of 119 | 26% of 91 | 54% of 119 | 68% of 117 | 59% of 81 |
| MCL Younger | 4, 25 | 3 × R-CHOP/R-DHAP | ASCT | RQ-PCR | 66% of 109 | 79% of 103 | 61% of 77 | 77% of 114 | 85% of 112 | 79% of 71 |
| Nordic MCL2 | 3, 34, 36 | 3 × R-maxiCHOP/R-HA | ASCT | Nested PCR | NR (88% of 42 stem cell products) | NR | NR | 92% of 79 | NR | NR |
| Nordic MCL3 | 26 | 3 × R-maxiCHOP/R-HA | Ibritumomab-tiuxetan + ASCT | Nested PCR | 53% of 99 | NR | NR | 83% of 107 | NR | NR |
| LYMA | 29 | 4 × R-DHAP | ASCT + rituximab maintenance or observation | RQ-PCR | NR | 80% of 120 | 66% of 98 | NR | 95% of 162 | 82% of 122 |
| CALGB 59909 | 30 | 2 × methotrexate + R-maxiCHOP | ASCT | RQ-PCR | NR | 46% of 39 | 36% of 39 | 74% of 27 | NR | NR |
| CALGB 50403 | 31, 32 | 2-3 × methotrexate + R-maxiCHOP | ASCT + bortezomib | RQ-PCR | NR | NR | 32% of 47 | NR | NR | NR |
| Seattle single-center report | 33 | R-hyperCVAD or R-CHOP-like | ASCT | MFC or PCR | 89% of 75 | NR | NR | NR | NR | NR |
| . | . | . | . | . | MRD negativity . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cohort . | Reference . | Induction . | Consolidation/maintenance . | MRD detection method . | At end of induction . | After consolidation . | ||||
| PB or BM . | PB . | BM . | PB or BM . | PB . | BM . | |||||
| Nordic MCL1 | 5 | 6 × maxiCHOP | ASCT | MFC or PCR | NR (0 of 16 stem cell products) | NR | NR | NR | NR | 38% of 13 |
| Kiel single-center report | 16 | 6 × CHOP-like | ASCT | RQ-PCR | 0 of 9 (6% of 17 stem cell products) | NR | NR | 52% of 27 | NR | NR |
| MCL Younger and MCL elderly | 4, 24, 25 | 6-8 × R-CHOP | ASCT or rituximab maintenance or interferon alpha maintenance | RQ-PCR | 40% of 225 | 53% of 216 | 34% of 156 | 48% of 209 | 58% of 205 | 56% of 117 |
| MCL Younger | 4, 25 | 6 × R-CHOP | ASCT | RQ-PCR | 34% of 126 | 47% of 119 | 26% of 91 | 54% of 119 | 68% of 117 | 59% of 81 |
| MCL Younger | 4, 25 | 3 × R-CHOP/R-DHAP | ASCT | RQ-PCR | 66% of 109 | 79% of 103 | 61% of 77 | 77% of 114 | 85% of 112 | 79% of 71 |
| Nordic MCL2 | 3, 34, 36 | 3 × R-maxiCHOP/R-HA | ASCT | Nested PCR | NR (88% of 42 stem cell products) | NR | NR | 92% of 79 | NR | NR |
| Nordic MCL3 | 26 | 3 × R-maxiCHOP/R-HA | Ibritumomab-tiuxetan + ASCT | Nested PCR | 53% of 99 | NR | NR | 83% of 107 | NR | NR |
| LYMA | 29 | 4 × R-DHAP | ASCT + rituximab maintenance or observation | RQ-PCR | NR | 80% of 120 | 66% of 98 | NR | 95% of 162 | 82% of 122 |
| CALGB 59909 | 30 | 2 × methotrexate + R-maxiCHOP | ASCT | RQ-PCR | NR | 46% of 39 | 36% of 39 | 74% of 27 | NR | NR |
| CALGB 50403 | 31, 32 | 2-3 × methotrexate + R-maxiCHOP | ASCT + bortezomib | RQ-PCR | NR | NR | 32% of 47 | NR | NR | NR |
| Seattle single-center report | 33 | R-hyperCVAD or R-CHOP-like | ASCT | MFC or PCR | 89% of 75 | NR | NR | NR | NR | NR |
Numbers indicate % MRD negative among evaluable patients in the respective compartment at the respective time point.
hyper CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; maxiCHOP, dose-intensified CHOP; NR, not reported.